Market Closed -
Japan Exchange
02:00:00 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
135
JPY
|
-0.74%
|
|
-1.46%
|
-22.86%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
17,198
|
26,206
|
29,588
|
18,560
|
20,511
|
12,007
|
-
|
-
|
Enterprise Value (EV)
1 |
11,566
|
21,101
|
25,067
|
13,998
|
14,133
|
5,928
|
6,178
|
6,278
|
P/E ratio
|
-27.5
x
|
-25.7
x
|
-36.3
x
|
-30
x
|
-66.6
x
|
-44.3
x
|
-67.5
x
|
-587
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.8
x
|
21.9
x
|
23
x
|
8.31
x
|
6.95
x
|
4.57
x
|
4.06
x
|
3.58
x
|
EV / Revenue
|
10.6
x
|
17.6
x
|
19.5
x
|
6.27
x
|
4.79
x
|
2.25
x
|
2.09
x
|
1.87
x
|
EV / EBITDA
|
-15.9
x
|
-25
x
|
-25.4
x
|
-23.8
x
|
-80.5
x
|
-14.8
x
|
-20.6
x
|
-44.8
x
|
EV / FCF
|
-17,766,522
x
|
-25,484,586
x
|
-35,206,167
x
|
-47,610,645
x
|
-46,953,130
x
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
2.43
x
|
4.33
x
|
5.49
x
|
2.58
x
|
2.71
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
71,066
|
71,407
|
71,641
|
81,760
|
85,107
|
88,941
|
-
|
-
|
Reference price
2 |
242.0
|
367.0
|
413.0
|
227.0
|
241.0
|
135.0
|
135.0
|
135.0
|
Announcement Date
|
5/14/19
|
7/10/20
|
5/12/21
|
5/13/22
|
5/12/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,088
|
1,199
|
1,286
|
2,234
|
2,953
|
2,630
|
2,960
|
3,350
|
EBITDA
1 |
-728.7
|
-842.7
|
-986.5
|
-587.4
|
-175.6
|
-400
|
-300
|
-140
|
EBIT
1 |
-781
|
-908
|
-1,048
|
-647
|
-356
|
-460
|
-370
|
-220
|
Operating Margin
|
-71.78%
|
-75.73%
|
-81.49%
|
-28.96%
|
-12.06%
|
-17.49%
|
-12.5%
|
-6.57%
|
Earnings before Tax (EBT)
1 |
-627
|
-1,015
|
-811
|
-573
|
-303
|
-260
|
-170
|
-20
|
Net income
1 |
-601
|
-1,016
|
-812
|
-575
|
-305
|
-260
|
-170
|
-20
|
Net margin
|
-55.24%
|
-84.74%
|
-63.14%
|
-25.74%
|
-10.33%
|
-9.89%
|
-5.74%
|
-0.6%
|
EPS
2 |
-8.790
|
-14.27
|
-11.38
|
-7.570
|
-3.620
|
-3.050
|
-2.000
|
-0.2300
|
Free Cash Flow
|
-651
|
-828
|
-712
|
-294
|
-301
|
-
|
-
|
-
|
FCF margin
|
-59.83%
|
-69.06%
|
-55.37%
|
-13.16%
|
-10.19%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/14/19
|
7/10/20
|
5/12/21
|
5/13/22
|
5/12/23
|
-
|
-
|
-
|
Fiscal Period: March |
2020 S1
|
2021 S1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
564
|
614
|
607
|
989
|
499
|
746
|
666
|
910
|
1,576
|
647
|
730
|
556
|
591
|
1,147
|
629
|
853.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-432
|
-502
|
-83
|
-359
|
-170
|
-118
|
-86
|
-4
|
-90
|
-117
|
-149
|
-124
|
-117
|
-241
|
-48
|
-170.7
|
Operating Margin
|
-76.6%
|
-81.76%
|
-13.67%
|
-36.3%
|
-34.07%
|
-15.82%
|
-12.91%
|
-0.44%
|
-5.71%
|
-18.08%
|
-20.41%
|
-22.3%
|
-19.8%
|
-21.01%
|
-7.63%
|
-20%
|
Earnings before Tax (EBT)
|
-434
|
-365
|
-
|
-201
|
-150
|
-
|
42
|
-
|
70
|
-106
|
-
|
73
|
-
|
61
|
-12
|
-
|
Net income
|
-436
|
-365
|
-
|
-201
|
-150
|
-
|
42
|
-
|
68
|
-107
|
-
|
72
|
-
|
60
|
-12
|
-
|
Net margin
|
-77.3%
|
-59.45%
|
-
|
-20.32%
|
-30.06%
|
-
|
6.31%
|
-
|
4.31%
|
-16.54%
|
-
|
12.95%
|
-
|
5.23%
|
-1.91%
|
-
|
EPS
2 |
-6.130
|
-5.130
|
-1.090
|
-2.790
|
-1.950
|
-2.830
|
0.5100
|
0.3100
|
0.8200
|
-1.290
|
-3.150
|
0.8500
|
-0.1400
|
0.7100
|
-0.1400
|
-3.620
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/13/19
|
11/12/20
|
11/12/21
|
11/12/21
|
2/10/22
|
5/13/22
|
8/10/22
|
11/9/22
|
11/9/22
|
2/10/23
|
5/12/23
|
8/10/23
|
11/10/23
|
11/10/23
|
2/9/24
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
5,632
|
5,105
|
4,521
|
4,562
|
6,378
|
6,079
|
5,829
|
5,729
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-651
|
-828
|
-712
|
-294
|
-301
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-9.1%
|
-15.6%
|
-14.2%
|
-9.1%
|
-4.1%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-8.9%
|
-12.7%
|
-12.5%
|
-7.17%
|
-1.45%
|
-
|
-
|
-
|
Assets
1 |
6,751
|
8,006
|
6,492
|
8,019
|
21,081
|
-
|
-
|
-
|
Book Value Per Share
|
99.50
|
84.80
|
75.20
|
88.10
|
89.00
|
-
|
-
|
-
|
Cash Flow per Share
|
-7.850
|
-13.20
|
-10.20
|
-6.820
|
-3.070
|
-
|
-
|
-
|
Capex
|
97
|
139
|
64
|
48
|
161
|
-
|
-
|
-
|
Capex / Sales
|
8.92%
|
11.59%
|
4.98%
|
2.15%
|
5.45%
|
-
|
-
|
-
|
Announcement Date
|
5/14/19
|
7/10/20
|
5/12/21
|
5/13/22
|
5/12/23
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -22.86% | 76.28M | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -16.09% | 15.36B | | -9.14% | 11.95B | | -17.69% | 11.6B | | -43.00% | 11.51B | | +5.24% | 8.71B |
Biopharmaceuticals
|